259
Participants
Start Date
June 2, 2022
Primary Completion Date
February 27, 2029
Study Completion Date
February 27, 2029
RO7204239
"RO7204239 will administered every 4 weeks (Q4W) by subcutaneous (SC) injection into the abdomen.~RO7204239 will be investigated at low- and high-dose in Part 1."
Placebo
Placebo will be administered Q4W by SC injection into the abdomen.
Risdiplam
Risdiplam will be administered orally once daily (QD) for the duration of the study.
Sydney Children's Hospital, Randwick
Chr de La Citadelle, Liège
UZ Gent, Ghent
Clinical Hospital Centre Zagreb, Zagreb
Columbia University Medical Center, New York
IRCCS Istituto Giannina Gaslini, Genoa
Fondazione IRCCS Istituto Neurologico ?Carlo Besta?, Milan
Asst Grande Ospedale Metropolitano Niguarda, Milan
Hospital Universitario La Paz, Madrid
Nemours Children's Hospital, Orlando
Hospital Universitario la Fe, Valencia
Ospedali Riuniti Torrette di Ancona, Ancona
Neurology & Neuromuscular Care Center, Denton
Boston Childrens Hospital, Boston
British Columbia Children's Hospital, Vancouver
The Hospital for Sick Children, Toronto
McGill University Health Centre - Glen Site, Montreal
Ospedale Pediatrico Bambino Gesù, Rome
Policlinico Agostino Gemelli, Rome
Kobe University Hospital, Hyōgo
Kagoshima University Hospital, Kagoshima
National Center for Global Health and Medicine, Tokyo
Universitair Medisch Centrum Utrecht, Utrecht
Instytut Centrum Zdrowia Matki Polki, ?ód?
Uniwersyteckie Centrum Kliniczne, Gda?sk
Uniwersytecki Szpital Kliniczny w Poznaniu, Późna
Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie, Warsaw
Instytut Pomnik Centrum Zdrowia Dziecka, Warsaw
CHULC, E.P.E. - Hospital Dona Estefania, Lisbon
Hospital de Santa Maria, Lisbon
Hospital Sant Joan De Deu, Esplugues de Llobregas
Hospital Vall d'Hebron, Barcelona
Birmingham Heartlands Hospital, Birmingham
Great Ormond Street Hospital For Children, London
John Radcliffe Hospital, Oxford
Hoffmann-La Roche
INDUSTRY